share_log

TrueShares Structured Outcome (April) ETF (NYSEARCA:APRZ) Stock Price Up 1.7%

Defense World ·  Sep 29, 2022 02:01

Shares of TrueShares Structured Outcome (April) ETF (NYSEARCA:APRZ – Get Rating) rose 1.7% on Wednesday . The company traded as high as $24.06 and last traded at $24.06. Approximately 155 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 1,034 shares. The stock had previously closed at $23.65.

TrueShares Structured Outcome (April) ETF Price Performance

The stock's 50-day moving average is $25.30 and its 200-day moving average is $25.45.

Hedge Funds Weigh In On TrueShares Structured Outcome (April) ETF

An institutional investor recently raised its position in TrueShares Structured Outcome (April) ETF stock. OLD Mission Capital LLC boosted its stake in TrueShares Structured Outcome (April) ETF (NYSEARCA:APRZ – Get Rating) by 65.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,185 shares of the company's stock after buying an additional 9,182 shares during the period. OLD Mission Capital LLC owned 9.27% of TrueShares Structured Outcome (April) ETF worth $560,000 at the end of the most recent quarter.

Recommended Stories

  • Get a free copy of the StockNews.com research report on TrueShares Structured Outcome (April) ETF (APRZ)
  • Can HCA Healthcare Weather the Normalization?
  • Can United Natural Foods Fight Both Inflation and the Fed?
  • Mullen Automotive Is Ready To Get In Gear
  • Cracker Barrel: A Tasty Treat Or Bad Apple?
  • Defensive Stocks For A Volatile Market

Receive News & Ratings for TrueShares Structured Outcome (April) ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrueShares Structured Outcome (April) ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment